UY25774A1 - Tabletas de valaciclovir que contienen dioxido de silicio coloidal - Google Patents

Tabletas de valaciclovir que contienen dioxido de silicio coloidal

Info

Publication number
UY25774A1
UY25774A1 UY25774A UY25774A UY25774A1 UY 25774 A1 UY25774 A1 UY 25774A1 UY 25774 A UY25774 A UY 25774A UY 25774 A UY25774 A UY 25774A UY 25774 A1 UY25774 A1 UY 25774A1
Authority
UY
Uruguay
Prior art keywords
valacyclovir
tablet
filler
silicon dioxide
lubricant
Prior art date
Application number
UY25774A
Other languages
English (en)
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25774(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of UY25774A1 publication Critical patent/UY25774A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una tableta que comprende al menos aproximadamente 50% en peso/peso de Valaciclovir o una sal del mismo, un rellenador de celulosa, un agente aglutinante, un lubricante de aproximadamente del 0.05 hasta aproximadamente el 3% en peso/peso de dióxido de silicio coloidal, caracterizada porque el valaciclovir o la sal del mismo está presente dentro de gránulos en la tableta, el dióxido de silicio lubricante y al menos una parción del rellenador celulósico están presentes extragranularmente; en donde la friabilidad de la tableta no excede del 1%, la dureza es de al menos 8kP, y la fuerza de eyección no excede de 1000 Newtons. El éster de L-valinato de (2-(2-amino-1,6-dihidro-6-oxo-purin-9-il)metoxi)etil, conocido como valaciclovir posee una potente actividad antiviral y se usa ampliamente en el tratamiento y profilaxis de infecciones virales en humanos, particularmente infecciones causadas por el grupo del virus del herpes. Se caracteriza porque el rellenador es celulosa microcristalina, el aglutinante es metilcelulosa o povidona, el lubricante es un derivado de estearato.
UY25774A 1995-01-20 1999-10-28 Tabletas de valaciclovir que contienen dioxido de silicio coloidal UY25774A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet

Publications (1)

Publication Number Publication Date
UY25774A1 true UY25774A1 (es) 2000-10-31

Family

ID=10768317

Family Applications (2)

Application Number Title Priority Date Filing Date
UY25774A UY25774A1 (es) 1995-01-20 1999-10-28 Tabletas de valaciclovir que contienen dioxido de silicio coloidal
UY25778A UY25778A1 (es) 1995-01-20 1999-10-29 Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal

Family Applications After (1)

Application Number Title Priority Date Filing Date
UY25778A UY25778A1 (es) 1995-01-20 1999-10-29 Proceso para preparar tabletas de valaciclovir que contiene dioxido de silicio coloidal

Country Status (39)

Country Link
US (1) US5879706A (es)
EP (1) EP0806943B1 (es)
JP (1) JP3350055B2 (es)
KR (1) KR100412298B1 (es)
CN (2) CN1313081C (es)
AP (1) AP666A (es)
AT (1) ATE190483T1 (es)
AU (1) AU710823B2 (es)
BG (1) BG63187B1 (es)
BR (1) BR9606769A (es)
CA (1) CA2210891C (es)
CY (1) CY2182B1 (es)
CZ (1) CZ296514B6 (es)
DE (1) DE69607146T2 (es)
DK (1) DK0806943T3 (es)
EA (1) EA000276B1 (es)
EE (1) EE03336B1 (es)
ES (1) ES2145425T3 (es)
FI (1) FI119722B (es)
GB (1) GB9501127D0 (es)
GE (1) GEP20022752B (es)
GR (1) GR3033677T3 (es)
HK (1) HK1002851A1 (es)
HU (1) HU226131B1 (es)
IL (1) IL116830A (es)
IN (1) IN181318B (es)
MY (1) MY126346A (es)
NO (1) NO311488B1 (es)
NZ (1) NZ298846A (es)
OA (1) OA10500A (es)
PL (1) PL185307B1 (es)
PT (1) PT806943E (es)
RO (1) RO118175B1 (es)
SK (1) SK282030B6 (es)
TR (1) TR199700657T1 (es)
UA (1) UA68325C2 (es)
UY (2) UY25774A1 (es)
WO (1) WO1996022082A1 (es)
ZA (1) ZA96448B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
JP4097698B2 (ja) * 1996-01-19 2008-06-11 グラクソ、グループ、リミテッド 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
SI20624A (sl) * 1998-12-18 2002-02-28 Abbott Laboratories Formulacija divalproeks natrija za kontrolirano sproščanje
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
MXPA03009391A (es) * 2001-05-01 2004-01-29 Pfizer Prod Inc METODO PARA FABRICAR UNA COMPOSICIoN FARMACEUTICA DE DOSIS BAJA.
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
US6849737B2 (en) * 2001-11-14 2005-02-01 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
ES2270172T3 (es) * 2002-10-16 2007-04-01 Teva Pharmaceutical Industries Ltd. Procedimiento para reducir alcoholes residuales en hidrocloruro de valaciclovir cristalino.
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
AU2003232719A1 (en) * 2003-05-30 2005-01-21 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
TW200510414A (en) * 2003-06-02 2005-03-16 Teva Pharma Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
ES2655435T3 (es) 2003-09-12 2018-02-20 Amgen Inc. Formulación de disolución rápida de cinacalcet
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
DE60301277T2 (de) * 2003-12-09 2006-03-30 Helm Ag Pharmazeutische zubereitung enthaltend valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
CN101484140B (zh) * 2006-05-10 2012-10-03 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
RU2446800C2 (ru) * 2006-05-31 2012-04-10 Вертекс Фармасьютикалз Инкорпорейтед Препаративные формы с контролируемым высвобождением
EP2040684B1 (en) * 2006-07-11 2013-01-23 LEK Pharmaceuticals d.d. Multiple unit tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
PT2407166E (pt) * 2009-03-13 2013-11-25 Toyama Chemical Co Ltd Comprimido e pó granulado que contêm 6-fluoro-3-hidroxi-2-pirazinacarboxamida
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
AU2021392532A1 (en) * 2020-12-01 2023-06-29 Lg Chem, Ltd. Oral formulation comprising 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid and method for preparing same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
EP0349103B1 (en) * 1988-05-04 1992-11-25 Smith Kline & French Laboratories Limited Chewable tablet
AU653203B2 (en) * 1991-01-30 1994-09-22 Wellcome Foundation Limited, The Water-dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
CN1494898A (zh) 2004-05-12
UA68325C2 (en) 2004-08-16
IL116830A (en) 2000-02-29
DE69607146D1 (de) 2000-04-20
PL321361A1 (en) 1997-12-08
KR19980701524A (ko) 1998-05-15
CN1179100A (zh) 1998-04-15
KR100412298B1 (ko) 2004-04-21
PL185307B1 (pl) 2003-04-30
NO973327D0 (no) 1997-07-18
SK96497A3 (en) 1998-01-14
EA000276B1 (ru) 1999-02-25
GR3033677T3 (en) 2000-10-31
CZ229297A3 (cs) 1998-02-18
HUP9801872A3 (en) 2001-02-28
NO973327L (no) 1997-09-16
NZ298846A (en) 1998-06-26
ES2145425T3 (es) 2000-07-01
DE69607146T2 (de) 2000-09-21
EE03336B1 (et) 2001-02-15
SK282030B6 (sk) 2001-10-08
GB9501127D0 (en) 1995-03-08
JPH10512564A (ja) 1998-12-02
CN1313081C (zh) 2007-05-02
DK0806943T3 (da) 2000-07-24
PT806943E (pt) 2000-08-31
ZA96448B (en) 1996-08-07
US5879706A (en) 1999-03-09
GEP20022752B (en) 2002-08-26
CA2210891C (en) 2009-05-19
BG63187B1 (bg) 2001-06-29
FI973062A0 (fi) 1997-07-18
UY25778A1 (es) 2000-08-21
RO118175B1 (ro) 2003-03-28
AP9701057A0 (en) 1997-10-31
CY2182B1 (en) 2002-08-23
NO311488B1 (no) 2001-12-03
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
HUP9801872A2 (hu) 1999-10-28
IN181318B (es) 1998-05-09
EP0806943B1 (en) 2000-03-15
CZ296514B6 (cs) 2006-03-15
BG101831A (en) 1998-04-30
MX9705459A (es) 1997-10-31
JP3350055B2 (ja) 2002-11-25
FI973062A (fi) 1997-09-18
TR199700657T1 (xx) 1998-02-21
AU710823B2 (en) 1999-09-30
WO1996022082A1 (en) 1996-07-25
FI119722B (fi) 2009-02-27
BR9606769A (pt) 1997-12-30
ATE190483T1 (de) 2000-04-15
HK1002851A1 (en) 1998-09-25
AP666A (en) 1998-08-24
AU4453496A (en) 1996-08-07
HU226131B1 (en) 2008-05-28
EA199700123A1 (ru) 1997-12-30
EP0806943A1 (en) 1997-11-19
MY126346A (en) 2006-09-29
OA10500A (en) 2002-04-10
IL116830A0 (en) 1996-05-14

Similar Documents

Publication Publication Date Title
UY25774A1 (es) Tabletas de valaciclovir que contienen dioxido de silicio coloidal
ES2157929T3 (es) Beta-d-dioxolano-nucleosidos enantiomeramente puros.
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
AR002270A1 (es) Clorhidrato de valaciclovir 2-[(2-amino-1,6-dihidro-6-oxo-9h-purin-9-il)metoxi]etil-l-valinato, uso para preparar un medicamento y proceso para obtener dicha forma cristalina
ES2058892T3 (es) Uso de omeprazol como agente antimicrobiano.
ES2139798T3 (es) Matriz de liberacion controlada para productos farmaceuticos.
MX9200361A (es) Nuevo uso del antagonista de adenosina.
EP0444196A4 (en) Agent for treatment and prophylaxis of ischemic disease of heart or brain
CZ226195A3 (en) The use of lamotrigin for preparing medicaments intended for treating neuronal degeneration caused by aids
MX9204394A (es) Derivados de amida del antibiotico a 40926, procedimiento para su preparacion y composicion farmaceutica que los contienen.
HUT52379A (en) Process for producing ribonucleotide reductase inhibitor, antiviral combinations comprising same, as well as pharmaceutical compositions comprising these combinations as active ingredient
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
BR9916043A (pt) Composto, uso do mesmo e de seus saisfarmaceuticamente aceitáveis, e, composiçãofarmacêutica para tratamento de infecções deherpes viral em pacientes
BG100599A (en) Antiviral form and therapeutical method
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
MC1930A1 (fr) Produit antiviral
ES2091941T3 (es) Potenciador del efecto antineoplasico y agente antineoplasico.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
AR005551A1 (es) Un producto de combinación farmacéutico que comprende un nucleósido análogo e inmunosupresores en combinación con un agente citotóxico para el tratamiento de infecciones con el virus del herpes simple
ATE207357T1 (de) Verwendung von cotinin zur linderung des tabakentzugssyndrom
ES2049711T1 (es) Uso de bucilamina para la fabricacion de un medicamento para el tratamiento de la cistinuria.
MX9302818A (es) Agente para incrementar somatostatina o para inhibir la reduccion de somatostatina.
AR005456A1 (es) Comprimidos y tabletas farmaceuticas que contienen 2-(2-(2-amino-9h-purin-9-il)etil)-1,3-propanodiol diacetato (famcicloviri) yprocedimiento para obtenerlos
ZA948908B (en) Use of 2-amino purine derivatives for the treatment and pro-phylaxis of human herpes virus 7 infection